BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Drug Discovery

MicuRx’s MRX-4 and Contezolid Show Favorable Safety and Efficacy in Phase III Trial for Diabetic Foot Infections

Data Monitoring Committee (DMC) has completed the first safety and efficacy assessment of the global Phase III clinical trial, recommending continued pro...

February 26, 2025 | News

Chime Biologics and Mabgeek Advance MG-K10 to U.S. Phase III Trials for Atopic Dermatitis and Asthma

Chime Biologics, a leading global CDMO that enables its partners' success in biologics, announced its continued collaboration with Mabgeek ...

February 24, 2025 | News

Sanyou Bio Advances Drug Discovery with 10-Trillion Molecule Platform

Sanyou Biopharmaceuticals Co., Ltd. (Sanyou Bio), a world-leading biotechnology company specializing in innovative biologic drug research and development, ...

February 24, 2025 | News

Harbour BioMed and Insilico Medicine Partner to Accelerate AI-Driven Antibody Discovery

Harbour BioMed, a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics focusing on...

February 21, 2025 | News

Syensqo and Emulseo Partner to Advance Microfluidic Innovations in Healthcare

Syensqo, a leading specialty chemicals company, is pleased to announce a strategic partnership with Emulseo, a French company specialized in formulations f...

February 21, 2025 | News

Australia Grants First Global Market Approval for YORVIPATH® to Treat Chronic Hypoparathyroidism

YORVIPATH® (palopegteriparatide) is now registered by the Therapeutic Goods Administration (TGA) for the treatment of chronic hypoparathyroidism...

February 21, 2025 | News

Adalvo and Wyntra Launch First Women’s Health Treatment in the UK, Expanding Access for Endometriosis Care

Adalvo, in collaboration with Wyntra announce a significant milestone with the first launch from Adalvo’s Women's Health portfolio in the UK, re...

February 20, 2025 | News

Ascletis’ ASC30 Oral Tablet Shows Promising Weight Loss in U.S. Phase Ib Obesity Trial

- ASC30 oral once-daily tablet demonstrated a 6.3% mean body weight reduction from baseline after 28-day treatment in multiple ascendi...

February 20, 2025 | News

Australia’s Clarity Pharmaceuticals Secures FDA Fast Track for 67Cu-SAR-bisPSMA in Prostate Cancer

Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation pr...

February 20, 2025 | News

South Korea’s Celltrion Secures EU Approval for Three Biosimilar Products, Expanding Its Portfolio to 11 by 2025

Celltrion gains simultaneous regulatory approval of two monoclonal antibody biosimilars across three treatments – Eydenzelt® (aflibe...

February 19, 2025 | News

Fosun Pharma Accelerates AI-Driven Transformation in Healthcare and Drug Development

Nowadays, artificial intelligence (AI) technology is profoundly reshaping the landscape of the pharmaceutical and healthcare industry. As a global innovati...

February 18, 2025 | News

TAHO Pharmaceuticals’ Apixaban Oral Dissolving Film Shows Positive Results in Pivotal Study

TAHO Pharmaceuticals announces positive preliminary results from the pivotal study of TAH3311, the world's first Apixaban oral dissolving film (ODF). The s...

February 18, 2025 | News

Kexing Biopharm Receives FDA Approval for Clinical Trials of GB05 Inhalation Therapy for Pediatric RSV Infections

Kexing Biopharm Co., Ltd. (Stock Code: 688136.SH) recently announced that the Investigational New Drug Application (IND) of GB05, Human Interferon α1...

February 17, 2025 | News

IASO Biotherapeutics’ New Drug Application for Equecabtagene Autoleucel Accepted by Hong Kong Department of Health

IASO Biotherapeutics ("IASO Bio"), a biopharmaceutical company focused on the discovery, development, manufacturing, and commercialization of innovative ce...

February 17, 2025 | News

Stay Connected